ProCE Banner Activity

CE / CME

Innovations in Treating Psychosis and Behavioral Disturbances in Dementia in Long-term Care Settings

Multimedia
Watch this on-demand webcast that includes resources and practical guidance to apply the most recent data, guidelines, and expert recommendations for the personalized treatment of patients with behavioral disturbances in dementia.

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Released: April 29, 2021

Expiration: April 28, 2022

No longer available for credit.

Share

Faculty

Anton P. Porsteinsson

Anton P. Porsteinsson, MD

William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine
University of Rochester School of Medicine and Dentistry
Rochester, New York

Pierre N. Tariot

Pierre N. Tariot, MD

Research Professor of Psychiatry
University of Arizona College of Medicine
Director, Banner Alzheimers Institute
Phoenix, Arizona

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This program is supported by an educational grant from

Acadia Pharmaceuticals, Inc.

Target Audience

This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses, pharmacists, social workers, and psychologists engaged in the care of patients with psychiatric disorders.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the prevalence of psychosis and behavioral disturbances in long-term care patients with dementia
  • Describe the differential diagnosis of psychosis in patients with dementia
  • Be familiar with the evidence-based treatments for psychosis and behavioral disturbances in patients with dementia

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Anton P. Porsteinsson, MD

William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine
University of Rochester School of Medicine and Dentistry
Rochester, New York

Anton P. Porsteinsson, MD, has disclosed that he has received consulting fees from Acadia, Alzheon, Avanir, Biogen, Cadent, Eisai, Functional Neuromodulation, MapLight Therapeutics, Sunovion, and Syneos and funds for research support from Alector, Athira, Avanir, Biogen, Biohaven, Eisai, Genentech/Roche, Lilly, and Vaccinex.

Pierre N. Tariot, MD

Research Professor of Psychiatry
University of Arizona College of Medicine
Director, Banner Alzheimers Institute
Phoenix, Arizona

Pierre N. Tariot, MD, has disclosed that he has received consulting fees from AbbVie, AC Immune, Acadia, Astex, Axsome, Biogen, Bioxcel, Cortexyme, Eisai, Genentech, Merck, Otuska, Syneos, and T3D and has ownership interest in Adamas.

Staff Disclosure

Staff

Mark Christiansen, PhD, PA-C

Mark Christiansen, PA-C, has no relevant conflicts of interest to report.

Stephanie Filice, LICSW

Stephanie Filice, LICSW, has no relevant conflicts of interest to report.

Prakash Masand, MD

Chief Medical Officer
Clinical Education Alliance
Adjunct Professor
Duke-NUS
New York, New York

Prakash Masand, MD, has disclosed that he has received consulting fees from AbbVie/Allergan, Acadia Pharmaceuticals Inc., Eisai, Intra-Cellular Therapies, Lundbeck, Sunovian, and Takeda; fees for non-CME services from AbbVie/Allergan, Intra-Cellular Therapies, Lundbeck, Sunovian, and Takeda; and funds for research support from AbbVie/Allergan.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Anne Roc, PhD

Director, Scientific Services

Anne Roc, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, NP, has no relevant conflicts of interest to report.

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Credit Designation

CCO designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-091-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 50% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until April 28, 2022. PAs should only claim commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 29, 2021, through April 28, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, competence, and performance of learners to assess diagnostic considerations and new and emerging therapies for the treatment of psychiatric illness.